The US Food and Drug Administration (FDA) has cancelled the planned November advisory committee (ODAC) meeting for Celgene's pomalidomide application. Celgene, in a press release, indicated that the pomalidomide application is continuing, which means that a decision with regard to pomalidomide is still expected on or before February 10, 2013.